指南与共识性腺与生殖内分泌

在线信息与男性性腺功能减退临床指南不一致:全球多语言内容分析

Discordance Between Online Information and Male Hypogonadism Clinical Guidelines: A Global Multilingual Content Analysis.
指南 / 共识 · J Clin Endocrinol Metab · 2026-01-01

该研究分析了全球253个提供睾酮治疗的网站内容,发现频繁出现与指南不符的宣传,如用于正常睾酮水平男性、宣称抗衰老或降低心血管风险。美国诊所此类非指南声明更多。作者建议国家监管机构加强执法。

要点

  • 提供睾酮治疗的网站常宣传非指南适应症,如抗衰老或心血管获益。
  • 24.4%的诊所常规使用非睾酮雄激素或促分泌剂治疗症状性低睾酮。
  • 9.9%的网站为血清睾酮正常(>12 nmol/L)的男性处方睾酮。

核心结论

  • 全球提供睾酮治疗的诊所网站频繁严重违反广告法规,可能对男性造成伤害。
  • 建议国家监管机构执行现有法律,使患者期望与临床指南一致。

研究设计与样本

  • 内容分析方法,使用概念和数据驱动策略制定编码框架。
  • 通过英语、阿拉伯语、印地语和西班牙语在3个搜索引擎检索,纳入253/1138个网站。
  • 网站分布:144个美国/加拿大,48个欧洲,17个澳大利亚,12个亚洲,11个南美,10个中东。

主要发现

  • 61/253(24.4%)诊所常规使用非睾酮雄激素或睾酮促分泌剂治疗症状性低睾酮。
  • 52/253(20.6%)网站声称睾酮治疗降低心血管风险。
  • 30/253(11.9%)网站声称微剂量改善治疗效果。
  • 25/253(9.9%)网站为血清睾酮正常(>12 nmol/L)的男性处方睾酮。
  • 25/253(9.9%)网站声称睾酮具有抗衰老效果。

临床怎么用

  • 临床医生应警惕患者从网络获取的睾酮治疗信息可能不符合指南。
  • 需主动向患者澄清睾酮治疗的适应症和证据,纠正错误认知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Testosterone prescriptions have increased up to 12-fold globally over the past 2 decades. EU and UK law tightly regulate the advertising of medical products. OBJECTIVE: To review the accuracy of publicly accessible information on websites offering testosterone treatment. DESIGN/SETTING: Content analysis methodology using concept- and data-driven strategies to develop a coding frame for data extraction. Publicly accessible websites offering testosterone prescriptions were identified using predefined search terms, conducted in English, Arabic, Hindi, and Spanish, across 3 search engines. Virtual private network searches within multiple geographical regions were used to reduce location bias. MAIN OUTCOME MEASURE: Accuracy of extracted data determined using international guidelines. RESULTS: A total of 253/1138 websites were included (144 US/Canada; 48 Europe; 17 Australia; 12 Asia; 11 South America; 10 Middle East). The following non-guideline-based practices (with numbers/percentages of clinics) were identified: routinely use nontestosterone androgens or testosterone secretagogues (eg, gonadotrophins) to treat symptomatic low testosterone (61/253; 24.4%); testosterone treatment reduces cardiovascular risk (52/253; 20.6%); microdosing improves treatment effects (30/253; 11.9%); testosterone is prescribed for men with normal serum testosterone (>12 nmol/L; 25/253;9.9%); testosterone has antiaging effects (25/253; 9.9%). US-based clinics more frequently made non-guideline-based claims compared with other geographical locations. CONCLUSION: We identify serious and frequent breaches of advertising law and regulations by clinics around the world offering testosterone treatment, with the potential to cause harm to men. We recommend enforcement of existing laws by national regulators to address this widespread public health challenge and align patient expectations with clinical guidelines for the safe treatment of men.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Grant B, de Silva NL, Gumssani M, et al. Discordance Between Online Information and Male Hypogonadism Clinical Guidelines: A Global Multilingual Content Analysis. J Clin Endocrinol Metab. 2026. PMID: 41489427. doi:10.1210/clinem/dgaf689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。